The US Food and Drug Administration (FDA) has granted Pfizer subsidiary Wyeth Pharmaceuticals approval of its Trumenba vaccine for the prevention of meningococcal disease caused by Neisseria meningitidis serogroup B in people ages 10 to 25, the first of its kind in the US. Previously the only meningococcal vaccines licensed in the US covered four of the five main disease-causing serogroups: A, C, Y and W. Another serogroup B vaccine, Novartis' Bexsero, was approved by the EU in January 2013 and is available in 34 countries. Trumenda was approved less than six months after Wyeth's submission under the FDA's breakthrough therapy program.
About this article
Cite this article
FDA OKs breakthrough B meningitis vaccine. Nat Biotechnol 33, 9 (2015). https://doi.org/10.1038/nbt0115-9a